BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Eli Lilly (LLY) reported positive Phase 3 TRIUMPH-1 results for retatrutide, a first-in-class once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist, in adults with obesity or overweight. At the 12 mg dose, participants lost an average of 70.3 lbs (28.3%) over 80 weeks. In an extension cohort of patients with BMI ≥35, weight loss reached 85.0 lbs (30.3%) at 104 weeks. 45.3% of participants on the 12 mg dose achieved ≥30% weight loss, a level long associated with bariatric surgery. Truist projected conservative peak sales of $12B to $19B. BMO anticipates a 2027 launch.
Lilly acquired Engage Biologics, a California-based preclinical biotech developing non-viral DNA delivery systems, bringing the company's 2026 deal count to seven.
BioMarin (BMRN) reported that Voxzogo (vosoritide) met its primary endpoint in a pivotal Phase 3 study in children with hypochondroplasia, potentially opening the path to the first approved treatment for the condition.
The FDA accepted Bayer's supplemental NDA for Kerendia (finerenone) with Priority Review for adults with type 1 diabetes and chronic kidney disease.
⚡ Executive Takeaway
Retatrutide is the most effective weight-loss drug ever tested in a Phase 3 trial. At the highest dose, participants lost an average of 70.3 pounds over 80 weeks, which is 28.3% of their body weight. Extension patients with BMI ≥35 lost 85 pounds (30.3%) at 104 weeks. For context: Zepbound (tirzepatide) delivered approximately 22% weight loss in its pivotal trial. Wegovy (semaglutide) delivered approximately 15%. Foundayo (orforglipron) delivered approximately 12%. Retatrutide at 28.3% is in a different category. Truist analysts wrote: "We believe these data set a new benchmark for anti-obesity medications and will support retatrutide approval and use in patients that are not adequately served with existing incretin options." The firm projected conservative worldwide peak sales of $12B to $19B. GlobalData forecasts $15.6B by 2031. BMO anticipates a 2027 launch. Lilly's Kenneth Custer said retatrutide "delivered a level of weight loss long associated with bariatric surgery." The triple agonist mechanism, hitting GIP, GLP-1, and glucagon receptors simultaneously, appears to produce meaningfully more weight loss than dual agonists (Zepbound) or single agonists (Wegovy, Foundayo). Safety was consistent with the incretin class: approximately one-third of participants reported nausea or diarrhea, with lower rates at the 4 mg dose. Seven more TRIUMPH Phase 3 readouts are expected in 2026, including TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease). 👉 Read Full Analysis
🔮 What To Watch
Retatrutide TRIUMPH-2 and TRIUMPH-3: Data from the T2D trial and the cardiovascular disease trial are expected in 2026. If retatrutide demonstrates CV risk reduction (like injectable Wegovy in SELECT), the commercial case expands further.
Retatrutide NDA Filing: BMO anticipates a 2027 launch, implying an NDA filing in late 2026 or early 2027. Watch for Lilly's filing announcement at the December 7 Investment Community Meeting.
Lilly's GLP-1 Portfolio Strategy: Lilly now has three tiers: Foundayo (oral, convenience play), Zepbound (injectable, established), and retatrutide (injectable, maximum efficacy). Each targets a different patient segment. The question is how Lilly sequences and prices them.
ASCO (9 days): Revolution Medicines plenary session May 31.
🚀 Top Story
Retatrutide Delivers 28.3% Weight Loss in Phase 3, Matching Bariatric Surgery LLY
What Happened: Eli Lilly announced positive topline results from the Phase 3 TRIUMPH-1 trial on May 21 evaluating retatrutide, a first-in-class once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist, in adults with obesity or overweight with at least one weight-related condition.
The Data:
12 mg dose (80 weeks): Mean weight loss of 70.3 lbs (28.3%). 45.3% of participants achieved ≥30% weight loss.
9 mg dose (80 weeks): Mean weight loss of 64.4 lbs (25.9%).
4 mg dose (80 weeks): Mean weight loss of 47.2 lbs (19.0%). Lower discontinuation rate due to adverse events versus placebo.
Extension (BMI ≥35, 12 mg, 104 weeks): Mean weight loss of 85.0 lbs (30.3%). Patients continued to lose weight beyond 80 weeks.
Improvements were observed in cardiovascular risk factors including waist circumference, cholesterol, and blood pressure.
Safety: Consistent with the incretin class. Approximately one-third reported nausea or diarrhea. Approximately one-quarter reported constipation. Vomiting ranged from 10% to 25% depending on dose. The 4 mg dose showed lower adverse event discontinuation rates than placebo.
Executive Impact: Truist: "We believe these data set a new benchmark for anti-obesity medications." Conservative peak sales estimate: $12B to $19B worldwide. BMO anticipates a 2027 launch. GlobalData forecasts $15.6B in 2031 sales. Scientific American's Daniel Drucker (University of Toronto) said: "If it's approved, this would be the drug that people who need to lose the most amount of weight would gravitate to." Seven more TRIUMPH Phase 3 readouts are expected in 2026: TRIUMPH-2 (T2D), TRIUMPH-3 (established CV disease), and trials in obstructive sleep apnea, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease.
🏢 Corporate & Business Developments
Lilly Acquires Engage Biologics in Its Seventh Deal of 2026 LLY
Lilly acquired Engage Biologics, a California-based preclinical biotech developing non-viral DNA delivery systems, according to The Pharma Letter. Financial terms were not disclosed. This is Lilly's seventh deal of 2026: Orna ($2.4B), Centessa ($7.8B), Kelonia ($7B), CrossBridge ($300M), Ajax ($2.3B), Profluent ($2.25B collaboration), and now Engage. Engage's non-viral DNA delivery platform complements Lilly's growing gene therapy portfolio (Kelonia lentiviral in vivo CAR-T, Orna circular RNA in vivo CAR-T, Profluent AI-designed recombinases) by adding a delivery approach that avoids viral vectors entirely, addressing the safety concerns highlighted by this week's AAV-linked brain tumor report.
🔬 Clinical & Research Updates
BioMarin's Voxzogo Hits Phase 3 in Hypochondroplasia BMRN
BioMarin reported that Voxzogo (vosoritide) met the primary endpoint in a pivotal Phase 3 study in children with hypochondroplasia, a rare skeletal condition causing short stature that is related to but milder than achondroplasia. The Pharma Letter said the data could "potentially open the way for the first approved treatment for the condition." Voxzogo is already approved for achondroplasia and generated significant revenue for BioMarin. The hypochondroplasia label expansion would extend the drug's franchise into a closely related rare disease with no current approved treatment.
🔬 Cardiovascular & Renal
FDA Grants Kerendia Priority Review for Type 1 Diabetes with CKD BAYN
The FDA accepted Bayer's supplemental NDA and granted Priority Review for Kerendia (finerenone) for adults with type 1 diabetes and chronic kidney disease, according to The Pharma Letter. Kerendia is currently approved for CKD associated with type 2 diabetes. Expanding to type 1 diabetes would add a patient population with significant unmet need for kidney-protective therapies.
📅 The Week Ahead
Late May: Commerce Section 232 report on medical devices expected
May 29: FDA RTCT public comment period closes
May 29 to June 2: ASCO Annual Meeting (Chicago)
May 31: ASCO plenary: RASolute 302 full data (RVMD)
June 4: Jefferies Global Healthcare Conference (New York)
🔓 BioMed Nexus Pro: Institutional Intelligence Brief
🧠 Retatrutide vs. the Field
Drug | Mechanism | Weight Loss | Duration | Status |
|---|---|---|---|---|
Retatrutide (Lilly) | GIP/GLP-1/glucagon triple | 28.3% (70.3 lbs) | 80 weeks | Phase 3 positive |
Retatrutide extension | Same, BMI ≥35 | 30.3% (85.0 lbs) | 104 weeks | Extension data |
Zepbound (Lilly) | GIP/GLP-1 dual | ~22% | 72 weeks | Approved |
Wegovy (Novo) | GLP-1 single | ~15% | 68 weeks | Approved |
Foundayo (Lilly) | GLP-1 oral | ~12% | 72 weeks | Approved |
Oral Wegovy (Novo) | GLP-1 oral | ~15% (estimated) | Ongoing | Approved |
Retatrutide's 28.3% at 80 weeks is not an incremental improvement. It is a step-change. The glucagon receptor agonism, which is the third mechanism on top of GIP and GLP-1, appears to drive additional energy expenditure and fat oxidation that dual agonists do not achieve.
The clinical implication: retatrutide will likely be positioned for patients with the most severe obesity (BMI ≥40 or ≥35 with comorbidities) where maximum weight loss is the clinical goal. Foundayo and Zepbound will serve patients with less severe obesity who prioritize convenience (oral) or established efficacy (dual agonist).
💊 Lilly's Three-Tier Obesity Portfolio
Lilly is building the broadest obesity franchise in pharma:
Tier 1: Foundayo (oral, convenience)
~12% weight loss. No food/water restrictions. $149/month self-pay.
Target: patients who prefer oral dosing, moderate obesity, initial therapy.
Tier 2: Zepbound (injectable, standard)
~22% weight loss. Once-weekly injection. Established franchise ($4.1B Q1 2026).
Target: patients seeking significant weight loss, established treatment paradigm.
Tier 3: Retatrutide (injectable, maximum efficacy)
28.3% weight loss. Once-weekly injection. 2027 launch expected.
Target: severe obesity, patients needing bariatric surgery-level results, those who have plateaued on dual agonists.
No other company has this depth. Novo has Wegovy (injectable) and oral Wegovy (pill). Kailera has ribupatide (injectable GIP/GLP-1). Amgen has MariTide. But none has a three-tier oral-dual-triple strategy covering the full obesity severity spectrum.
📊 Peak Sales: Why $12B to $19B May Be Conservative
Truist projected $12B to $19B as "conservative" worldwide peak sales. GlobalData estimates $15.6B by 2031. The reasoning:
The global obesity market is projected to exceed $200B by 2030. Retatrutide will not replace Zepbound or Foundayo; it will expand the treatable population by reaching patients for whom existing options do not deliver sufficient weight loss. The 45.3% of patients achieving ≥30% weight loss is a powerful commercial message: nearly half of patients on the highest dose achieve results comparable to bariatric surgery without surgery.
The bear case: pricing, insurance coverage, and manufacturing capacity for a third injectable GLP-1 from the same company. Payers may resist covering three tiers from one manufacturer. But the clinical differentiation (28% vs. 22% vs. 12%) makes a formulary argument that is hard to deny.
🎯 Catalyst Calendar: May 2026 Forward
Date | Event | Tickers |
|---|---|---|
Late May | Commerce Section 232 report on medical devices expected | MDT, BSX, SYK, ISRG |
May 29 | FDA RTCT public comment period closes | N/A |
May 29 to June 2 | ASCO Annual Meeting (Chicago) | Multiple |
May 31 | ASCO plenary: RASolute 302 full data | RVMD |
June 4 | Jefferies Global Healthcare Conference (New York) | Multiple |
June 2026 | Takeda CEO transition (Julie Kim) | TAK |
2026 | TRIUMPH-2 (retatrutide T2D) readout expected | LLY |
2026 | TRIUMPH-3 (retatrutide CV disease) readout expected | LLY |
Late Q2 | Lilly Foundayo T2D filing under CNPV | LLY |
Q3 2026 | Revolution Medicines daraxonrasib approval projected (Truist) | RVMD |
July 1 | Medicare GLP-1 Bridge program launches | LLY, NVO |
Q3 2026 | Teva/Emalex close expected | TEVA |
July 31 | Section 232 pharma tariffs effective (large companies) | Multiple |
H2 2026 | Foundayo T2D regulatory action expected | LLY |
H2 2026 | Lilly/Kelonia close expected | LLY |
H2 2026 | Ajax proof-of-concept data expected | LLY |
H2 2026 | Merck sac-TMT filing expected | MRK |
2027 | Retatrutide launch anticipated (BMO) | LLY |
Sept 19 | Ultragenyx UX111 PDUFA (Sanfilippo Type A gene therapy) | RARE |
Sept 29 | Section 232 pharma tariffs effective (all other companies) | Multiple |
Dec 7 | Lilly Investment Community Meeting | LLY |
Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →
Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →